Symbols

ENOV

Enovis·NYSE

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ENOV

Enovis Corporation

A global orthopedic company that develops and commercializes innovative biologic and synthetic products for musculoskeletal and sports medicine applications

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

05/08/2008

Exchange

New York Stock Exchange

Full-time Employees

7,802

Fiscal Year Ends

12-31

Website

www.enovis.com

Security Type

Common stock

Office address

2711 Centerville Road, Suite 400, Wilmington, Delaware 19808

Business

Introduction

Enovis Corporation was established in 1995. The company is an innovation-driven medical technology growth company that develops clinically differentiated solutions that generate better patient outcomes and transform workflows. Driven by the continuous improvement of global talent and innovation culture, the company's extensive products, services and comprehensive technologies all drive active lifestyles in orthopedics and other fields.

Company Financials

EPS

ENOV has released its 2025 Q4 earnings. EPS was reported at 0.95, versus the expected 0.82, beating expectations. The chart below visualizes how ENOV has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ENOV has released its 2025 Q4 earnings report, with revenue of 575.76M, reflecting a YoY change of 2.64%, and net profit of -520.45M, showing a YoY change of 25.99%. The Sankey diagram below clearly presents ENOV's revenue sources and cost distribution.